tbuckley/cabot-search huggingface dataset:
RARE-12. ADULT PILOCYTIC ASTROCYTOMA: AN INSTITUTIONAL SERIES AND SYSTEMATIC LITERATURE REVIEW FOR EXTENT OF RESECTION AND RECURRENCE
Authors: Kamila M. Bond, Joshua D. Hughes
Journal: Neuro-Oncology (2016)

Pilocytic astrocytomas (PA) rarely occur in adults. We present a case series and systematic literature review of adult pilocytic astrocytoma (APA), examining presentation, treatment, and outcome. We retrospectively reviewed our records from 1998 to 2010 for consecutive cases of PA in patients ≥18 years. A systematic literature review identified thirty-eight English-language studies with pathology-proven APA. At our institution, forty-six patients were diagnosed with PA; mean age was 33.6 ± 13.3 (18-76) years and 24 (52%) were female. Follow-up was available in 41 (89%) patients with mean follow-up of 76.3 ± 52.9 (1-204) months. Patients presented with headache (41%), seizure (21%), hydrocephalus (17%), and hemorrhage (2%). Twenty-five (54%) tumors were infratentorial and 21 (46%) supratentorial. Twenty-two (54%) patients underwent gross-total resection (GTR), 15 (37%) subtotal resection (STR), 2 (4%) observation following biopsy, and 2 (4%) radiotherapy alone. Permanent postoperative deficits occurred in 3 (7%) patients and included hemiparesis and cranial nerve palsy. Tumors recurred or progressed in 7 (15%) patients treated by STR (5/7) or radiotherapy alone (2/7) after 80.1 ± 38.7 (31-126) months. Five patients underwent a second surgery. Thirty-nine (95%) of patients were still alive at last follow-up. A systematic literature review identified 38 studies on APA with a total of 415 patients; mean age was 31.4 ± 12.5 (18-75) years and 218 (53%) were female. Including our study, six studies reported follow-up, extent of resection, and recurrence. Out of 233 patients with a weighted mean follow-up of 65.1 (1-420) months, 114 (49%) had GTR and 119 (51%) STR. Eighty-seven (37%) patients recurred, 23(20%) after GTR and 64(54%) after STR (p=0.0001). 86% of patients were still alive at last follow-up. Though rare, adult pilocytic astrocytoma can present over a wide range of ages. GTR should be the goal of surgery when possible as tumor recurrence is more likely after STR. However, this is not always feasible. Prognosis is generally favorable and overall survival can be excellent.
Genetic and Metabolic Determinants of Methotrexate Induced Mucositis in Pediatric Acute Lymphoblastic Leukemia
Authors: Marissa den Hoed, E. Lopez-Lopez, Mariël L. Te Winkel, Wim Tissing, Jasmijn de Rooij, A. Gutierrez-Camino, A. Garcia-Orad, E. den Boer, Rob Pieters, S.M.F. Pluijm, R. de Jonge, Marry M. van den Heuvel-Eibrink
Journal: Blood (2014)
Acquired expression of CblQ367P in mice induces dysplastic myelopoiesis mimicking chronic myelomonocytic leukemia
Authors: Yuichiro Nakata, Takeshi Ueda, Akiko Nagamachi, Norimasa Yamasaki, Ken-ichiro Ikeda, Yasuyuki Sera, Keiyo Takubo, Akinori Kanai, Hideaki Oda, Masashi Sanada, Seishi Ogawa, Kohichiro Tsuji, Yasuhiro Ebihara, Linda Wolff, Zen-ichiro Honda, Toshio Suda, Toshiya Inaba, Hiroaki Honda
Journal: Blood (2017)
Three dimensional distribution of surfactant in microspheres revealed by synchrotron radiation X-ray microcomputed tomography
Authors: Li Wu, Manli Wang, Vikramjeet Singh, Haiyan Li, Zhen Guo, Shuangying Gui, Peter York, Tiqiao Xiao, Xianzhen Yin, Jiwen Zhang
Journal: Asian Journal of Pharmaceutical Sciences (2017)

This study investigated the formulation mechanism of microspheres via internal surfactant distribution. Eudragit L100 based microspheres loaded with bovine serum albumin were prepared by solid in oil in oil emulsion solvent evaporation method using acetone and liquid paraffin system containing sucrose stearate as a surfactant. The fabricated microspheres were evaluated for encapsulation efficiency, particle size, production yield, and in vitro release characteristics. The internal structures of microspheres were characterized using synchrotron radiation X-ray microcomputed tomography (SR-µCT). The enhanced contrast made the sucrose stearate distinguished from Eudragit to have its three dimensional (3D) distribution. Results indicated that the content and concentration determined the state of sucrose stearate and had significant influences on the release kinetics of protein. The dispersity of sucrose stearate was the primary factor that controlled the structure of the microspheres and further affected the encapsulation efficiency, effective drug loading, as well as in vitro release behavior. In conclusion, the 3D internal distribution of surfactant in microspheres and its effects on protein release behaviors have been revealed for the first time. The highly resolved 3D architecture provides new evidence for the deep understanding of the microsphere formation mechanism.
Judith Eve Kingston
Authors: M Ashwin Reddy
Journal: BMJ (2017)

Judith Eve Kingston was an incredibly dedicated paediatric oncologist, who shaped the treatment of retinoblastoma in the UK and around the world. She was the driving force in the team at St Bartholomew’s Hospital that started the transition from radiotherapy towards chemotherapy for young children with retinoblastoma. She was acknowledged around the world, and a memorial lecture will be given in her honour at the International Society of Ocular Oncology in Sydney, Australia, in …
Motexafin Gadolinium (Mgd), a Redox Stress Inducer, Lowers p53 Protein but Not Message in Lymphoma Cell Lines: Mechanisms of Reactive Oxygen Species (ROS)-Mediated Apoptosis in Lymphoma.
Authors: Amareshwar Singh, Sheila Prachand, Andrew M. Evens, Paul Schumacker, Leo I. Gordon
Journal: Blood (2006)
Assessment and Management of Iron Overload in β-Thalassemia Major Patients in Italy: A Real-Life Experience From the Webthal® Project
Authors: Antonio Piga, Filomena Longo, Khaled M Musallam, Maria Domenica Cappellini, Gian Luca Forni, Giovanni Quarta, Francesco Chiavilli, Francesca Valeria Commendatore, Sergio Mulas, Vincenzo Caruso, Renzo Galanello
Journal: Blood (2012)
Phase III trial of 24 weeks vs. 48 weeks capecitabine adjuvant chemotherapy for patients with stage III colon cancer: Final results of JFMC37-0801
Authors: S. Yamaguchi, K. Kunieda, T. Sato, Y. Naramoto, M. Kobayashi, Y. Ogata, T. Furuhata, Y. Takii, M. Kusunoki, Y. Maehara, K. Koda, K. Okuno, M. Ohno, H. Mishima, S. Sadahiro, C. Hamada, J. Sakamoto, S. Saji, N. Tomita
Journal: Annals of Oncology (2016)
Factors associated with disconcordance of KRAS, NRAS, BRAF, PIK3CA mutation status in the primary tumor and metastases in patients (pts) with colorectal cancer (CRC)
Authors: M. Fedyanin, A. Stroganova, A. Senderovich, S. Dranko, A. Tryakin, E. Polyanskaya, A. Popova, O. Sekhina, A. Rasulov, S. Gordeev, I. Sagaydak, S. Tjulandin
Journal: Annals of Oncology (2016)
Effects of simultaneous care on quality of life of advanced cancer patients. A multicenter controlled randomised clinical trial
Authors: V. Franciosi, G. Caruso, C. Degli Esposti, L. Cavanna, R. Berte', G.P. Bacchini, L. Bocchi, M. Monfredo, P. Di Cesare, B. Melotti, E. Piva, V. Scafuri, G. Maglietta, M. Sequino, A. RIMANTI, C. Binovi, F. GHISONI, C. Caminiti
Journal: Annals of Oncology (2016)
Interferon-Gamma Signaling in the Pathogenesis of Idiopathic Pneumonia Syndrome Following Allogeneic Bone Marrow Transplantation
Authors: Hui-Hui Ma, Biin Sung, Caisheng Lu, Liangsong Song, Rika Gomi, Wenzhu Wu, Jing Fu, Suzanne Lentzsch, Stefan Worgall, Markus Mapara
Journal: Blood (2015)
RARE-30. CLINICAL AND MOLECULAR CHARACTERIZATION OF GLIONEURONAL TUMORS
Authors: Julie Miller, Corey Gill
Journal: Neuro-Oncology (2016)

To describe the clinical characteristics and molecular features of patients with glioneuronal tumors managed at the Massachusetts General Hospital. Glioneuronal tumors are a rare tumor type with mixed neuronal and glial lineage. In recent years new subtypes have been described but the overall clinical characteristics and molecular phenotype have not been formally catalogued. We performed a retrospective chart review of clinical records of 23 patients diagnosed with glioneuronal tumors between 1999 and 2015, including clinical, pathologic and immunohistochemical data available. The median age of patient population with glioneuronal tumors (GNT) in our database is 31 years (range of 15-71) with an even gender distribution. The most common presenting feature is headache (10/23), followed by seizure (7/23). GNTs were more likely to be supratentorial (14/23) than infratentorial (8/23). Twenty of 23 patients underwent surgical resection and, during a median time of follow-up of 9 years, 14 of 23 patients (60.9%) have remained stable on clinical and radiologic grounds. A subset of patients received treatment with radiation (34.7%), chemotherapy (temozolomide or bevacizumab, 30.4%) or the combination (26.1%). The majority of tumors had low proliferative index on histologic analysis. Immunohistochemistry for IDH R132H mutation was negative in all cases that were tested (7/7). Glioneuronal tumors are a lower grade tumor type which tends to affect younger age groups and take on a less aggressive course than tumors of the glioma lineage, with low rates of proliferation on histologic analysis. A subset of these tumors are progressive, however, and further characterization at the molecular level with be helpful to better understanding the behavior.
GENT-32. COMPREHENSIVE TRANSCRIPTOMIC ANALYSIS OF PEDIATRIC AND ADULT HUMAN BRAIN TUMORS FOR DISCOVERY OF BRAIN TUMOR-ASSOCIATED LONG NON-CODING RNAS
Authors: Yashar Niknafs, Abhijit Parolia
Journal: Neuro-Oncology (2016)

Long non-coding RNAs (lncRNAs) have been shown to play a role in normal physiology development, and in cancers. Their discovery on a large scale has been made possible by recent comprehensive sequencing efforts to generate a wealth of RNA-seq data by multiple consortia. In a previous pan-cancer analysis, we identified 361 lncRNAs with brain cancer specific expression, from a cohort containing 398 brain tumors (Iyer and Niknafs et al., Nature Genetics, 2015). We propose to build on these studies to interrogate the transcriptome of the normal brain and a multitude of brain cancers including adult and pediatric brain tumors. To achieve this we have analyzed 2,354 brain RNA-seq samples of the following categories: 1,403 normal adult brain tissue samples, 612 low-grade gliomas tumors, 175 glioblastomas (with an additional 13 matched samples pre- and post-temozolamide treatment), 72 pilocytic astrocytomas, 45 medulloblastomas, and 34 prefrontal cortex samples throughout development. Following RNA-seq read alignment and transcript structure prediction, our lncRNA discovery pipeline employs a novel technique of transcriptome meta-assembly, called TACO (tacorna.github.io), that generated a consensus brain transcriptome from the 2,354 input samples. In these samples we have discovered 26,071 previously unannotated genes. Analysis of these novel brain transcripts revealed a myriad of lncRNAs with expression specific to brain tumors versus the non-neopalstic brain. Further, we have identified lncRNAs specific to the various tumor types and subtypes, and to the development of temozolomide resistance. The discovery of these novel lncRNA genes will spur further downstream biological investigation of their role in brain cancer disease progression, and their potential to serve as therapeutic targets or biomarkers.
68Ga-Exendin-4 PET/CT in Evaluation of Endoscopic Ultrasound–Guided Ethanol Ablation of an Insulinoma
Authors: Yaping Luo, Ji Li, Aiming Yang, Hongbo Yang, Fang Li
Journal: Clinical Nuclear Medicine (2017)

A 32-year-old man with endogenous hyperinsulinemic hypoglycemia was clinically diagnosed with an insulinoma. Conventional imaging result was negative, and a previous exploratory laparotomy with distal pancreatectomy failed to detect the tumor. Ga-exendin-4 PET/CT showed a lesion with intense radioactivity in the head of the pancreas suggestive of an insulinoma, and endoscopic ultrasound-guided ethanol ablation was performed. Postablation evaluation with Ga-exendin-4 PET/CT showed markedly decreased radioactivity of the tumor. The symptoms and blood glucose monitoring also suggested partial response of the insulinoma.
RTHP-11. RECEIPT OF RADIATION TREATMENT FOR ACOUSTIC NEUROMA: A NATIONAL CANCER DATABASE ANALYSIS OF THE IMPACT OF RACE AND INSURANCE STATUS
Authors: Shearwood McClelland, James D Murphy, Charles R Thomas
Journal: Neuro-Oncology (2016)

Following acoustic neuroma (AN) surgery, in-hospital mortality differs by patient race and insurance status (McClelland et al., 2011); however the impact of these demographics on the receipt of radiation for AN has not been addressed. The National Cancer Data Base (NCDB) from 2004-2013 identified patients receiving radiation as solitary AN treatment. A multivariable logistic regression model was used to characterize patients who received radiation, adjusting for patient age, sex, income, comorbidities, and tumor size. A total of 623 AN patients received radiation as solitary treatment. Patients at least age 65 (OR=2.2;95%CI=1.7-2.9;p<0.0001), having a high-school degree (OR=1.3;95%CI=1.0-1.5;p=002) or treated in a comprehensive cancer center (OR=1.5;95%CI=1.3-1.9;p=0.02) were more likely to receive radiation. Patients on Medicaid (OR=0.8;95%CI=0.5-1.2;p=0.04), having median household income of at least $48,000 (OR=0.8;95%CI=0.6-0.9;p=0.01), a Charlson/Deyo score of one (OR=0.6;95%CI=0.4-0.7;p=0.02) or residing in the western United States (OR=0.5;95%CI=0.4-0.7;p=0.03) were less likely to receive radiation. Patient gender, race or tumor size did not impact receipt of radiation. Patients who were elderly, had a high-school degree, or were treated in comprehensive cancer centers were more likely to receive radiation for AN. Conversely, patients on Medicaid, having a Charlson/Deyo score of one, residing in the western United States, or with minimum household income of $48,000 were less likely to receive radiation for AN; receipt of radiation was not impacted by race. These findings indicate that patients with advanced age and/or treated at comprehensive cancer centers are being triaged to radiation for AN independent of race. Long-term nationwide outcome analyses will be needed to determine whether post-treatment outcomes remain uninfluenced by race.
Specific Inhibition of hTERT by shRNA Sensitizes for Imatinib Mesylate in BCR-ABL-Positive Cells.
Authors: Goro Sashida, Tetsuzo Tauchi, Masahiko Sumi, Akihiro Nakajima, Junko H. Ohyashiki, Kazuma Ohyashiki
Journal: Blood (2004)
Pulmonary Opacities and Bronchiectasis Avid on 68Ga-PSMA PET
Authors: Kirsten Bouchelouche, Mikkel Holm Vendelbo
Journal: Clinical Nuclear Medicine (2017)

Prostate-specific membrane antigen (PSMA) is highly expressed in prostate cancer, and the expression increases with tumor aggressiveness, metastatic disease, and recurrence. Despite its name, PSMA is also expressed in neovasculature of other tumors including lung cancer. Here, we demonstrate a case of increased PSMA expression on Ga-PSMA PET/CT in benign lung opacities and bronchiectasis in a prostate cancer patient. Thus, increased PSMA activity in the lungs may be due to both benign and malignant diseases and warrants further evaluation.
Lenalidomide Exhibits Activity in Mantle Cell Lymphoma through Increased NK Cell Mediated Cytotoxicity
Authors: Patrick Hagner, Hsiling Chiu, Maria Ortiz-Estevez, Tsvetan Biyukov, Carrie Brachman, Marek Trneny, Luca Arcaini, Franck Morschhauser, Antoine Thyss, Stephan Stilgenbauer, Noel Milpied, Reinhard Marks, Pellegrino Musto, Giovanni Martinelli, Carla Heise, Thomas Daniel, Rajesh Chopra, James Carmichael, Matthew Trotter, Anita K. Gandhi, Anjan Thakurta
Journal: Blood (2015)
Predictive role of absolute lymphocyte count (alc) and neutrophil/lymphocyte ratio (nlr) in patients with metastatic non small cell lung cancer (nsclc) treated with nivolumab: results of a retrospective monocentric study
Authors: S. Canova, P. Bidoli, P. Lissoni, M.I. Abbate, S. Capici, S. Casiraghi, D. Cortinovis
Journal: Annals of Oncology (2016)
RARE-63. MULTICENTRIC GLIOMA IN OLLIER DISEASE: A CASE REPORT AND REVIEW OF THE LITERATURE
Authors: Rebecca A. Harrison, Gregory N. Fuller, Sujit S. Prabhu, John M. Slopis, Marta Penas-Prado
Journal: Neuro-Oncology (2016)

To discuss a case of multicentric glioma in a patient with Ollier disease (OD) and review the literature surrounding this association. OD is a subtype of multiple enchondromatosis, characterized by hamartomatous proliferation of chondrocytes in long bones. Extra-osseous tumors have been increasingly reported in this condition, with a particular predisposition towards gliomagenesis. Presentation of an illustrative case and literature review of gliomas in patients with OD. A 26-year-old male with OD initially presented at age 15 years with a left skull base chondroma. This dedifferentiated to a chondrosarcoma, requiring resection and radiation therapy. At age 22 years, bifrontal MRI changes consistent with low-grade glioma were identified. Biopsy of the right frontal lesion demonstrated oligodendroglioma, IDH-mutant, 1p/19q-codeleted, WHO grade II. Despite adjuvant chemotherapy with temozolomide (TMZ), there was radiographic progression after treatment discontinuation. TMZ therapy was resumed; however, radiographic progression of the left frontal lesion led to surgical resection. A histologic diagnosis of anaplastic oligodendroglioma, WHO grade III, was rendered. Despite radiation therapy and adjuvant procarbazine and lomustine, the left frontal lesion demonstrated enlargement and high-grade features; repeat resection yielded an integrated diagnosis of glioblastoma, IDH-mutant, negative for 1p/19q codeletion (1p loss, 19q intact). This case reinforces the association between OD and gliomagenesis. Additionally, multicentric glioma in OD is exceptional. The mutant isocitrate dehydrogenase (IDH) 1 pathway in this patient’s gliomas may represent the driving oncogenic pathway for his condition. Increasing evidence supports the concept of somatic heterozygous mutations of IDH1 and IDH2 playing a central role in tumorigenesis in OD, with this aberrant pathway contributing to the development of both mesenchymal and glial tumors. Further characterization of gliomas in OD is essential to our understanding of their pathogenesis, and may illuminate potential therapeutic avenues for glioma arising in the setting of OD.
Multicenter Phase II Study of the CyclOBEAP Plus Rituximab in Diffuse Large B-Cell Lymphoma with Analysis of Biomakers.
Authors: Nozomi Niitsu, Mika Kohri, Yuki Hagiwara, Ken Tanae, Handa Kohsuke, Naoki Takahashi, Masami Bessho, Masataka Okamoto
Journal: Blood (2009)
RARE-31. OUTCOME AND PROGNOSTIC FEATURES FOR PEDIATRIC PINEAL GLAND TUMORS
Authors: Kailin Yang, Leo Kim, Violette Recinos, John Suh, Samuel Chao, Erin Murphy
Journal: Neuro-Oncology (2016)

Pineal gland tumor is a rare type of brain neoplasm, which typically occurs in children and young adults. However, systematic study of pineal gland tumor has been difficult given its low incidence. Using NCI Surveillance, Epidemiology, and End Results registry (1973-2012), we identified 593 patients of age 18 or younger with the diagnosis of malignant tumor located in pineal gland. The impact of radiotherapy (RT) and surgery on overall survival (OS) was determined using Log-rank test and multivariate Cox proportional hazard modeling. The major histological categories were germ cell tumor (GCT, 64.9%) and pineal parenchymal tumor (PPT, 28.3%). RT was delivered to 71.3% of patients. 11.5% of patients underwent sub-total resection (STR), while 20.2% underwent gross total resection (GTR). OS for all patients at 10 years was 69.3%. Pediatric patients with GCT were predominantly male (93.0%), and that for PPT was only 48.8% (p<0.01). The mean age for GCT is 13.1 years while that for PPT was 7.7 years (p<0.01). OS at 10 years was better for GCT (79.4%) than for PPT (47.5%). Using multivariate analysis, the delivery of RT was associated with improved OS among all 593 pineal gland tumor patients (HR 0.505, 95% CI 0.360-0.719, p<0.01). Specifically, RT was found to prolong OS in patient subgroups with germinoma (HR 0.286, 95% CI 0.137-0.624, p<0.01) or PPT (HR 0.387, 95% CI 0.233-0.646, p<0.01), but no survival benefit was seen for RT among patients with nongerminomatous GCT (HR 0.668, 95% CI 0.313-1.398, p=0.32). Histology is an important prognostic factor for pediatric patients with pineal gland tumor, with male predominance, older age at diagnosis, and improved OS for GCT compared to PPT. Our study also suggests beneficial effect of RT to prolong OS among all patients and those within subgroups of GCT or PPT.
The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia
Authors: Nina Fenouille, Christopher F Bassil, Issam Ben-Sahra, Lina Benajiba, Gabriela Alexe, Azucena Ramos, Yana Pikman, Amy S Conway, Michael R Burgess, Qing Li, Frédéric Luciano, Patrick Auberger, Ilene Galinsky, Daniel J DeAngelo, Richard M Stone, Yi Zhang, Archibald S Perkins, Kevin Shannon, Michael T Hemann, Alexandre Puissant, Kimberly Stegmaier
Journal: Nature Medicine (2017)
Survivin in Multiple Myeloma: Prognostic and Therapeutic Implications
Authors: Verena Wagner, Dirk Hose, Anja Seckinger, Ludmila Weitz, Tobias Meißner, Thierry Reme, Jean-Francois Rossi, Hartmut Goldschmidt, Alwin Krämer, Bernard Klein, Marc S Raab
Journal: Blood (2011)
Identification of Apolipoprotein E Receptor 2′ as the Low-Density Lipoprotein Receptor on Platelets.
Authors: Jan-Willem N. Akkerman, Suzanne J.A. Korporaal, Ingrid A.M. Relou, Miranda Van Eck, Martineke Bezemer, Gertie Gorter, Theo J.C. Van Berkel, Johannes Nimf, Peter J. Lenting
Journal: Blood (2004)
Increased Bone Resorption Is Implicated in the Pathogenesis of Bone Loss in Hemophilia Patients: Correlations with Severity of Hemophilic Arthropathy and HIV Infection.
Authors: O. Katsarou, Evangelos Terpos, P. Hatzismalis, S. Provelengios, T. Adraktas, D. Hadjidakis, A. Kouramba, S.A. Raptis, A. Karafoulidou
Journal: Blood (2007)
Defining the Pathophysiology of Pure Red Cell Aplasia Due to Feline Leukemic Virus Subgroup C Receptor (FLVCR) Dysfunction: Does Heme Toxicity Account for the Erythroid Marrow Failure?
Authors: Sioban B Keel, Marilyn Sanchez-Bonilla, Li Liu, Yan Wang, Janis L. Abkowitz
Journal: Blood (2011)
PACER – A multicentre, single-arm, two-stage, phase 2 study of panitumumab in patients with cetuximab-refractory metastatic colorectal cancer (mCRC)
Authors: B. Daniele, R.V. Iaffaioli, C. Chiara, E. Maiello, G. Rosati, O. Alabiso, G. Nasti, A. De Stefano, T.P. Latiano, D. Bilancia, E. Barletta, A. Ottaiano, C. Romano, L. Silvestro, A. Avallone, M. Lambiase, N. Normanno, G. Daniele, F. Perrone, M.C. Piccirillo
Journal: Annals of Oncology (2016)
Survival in young adults diagnosed with follicular lymphoma in a national registry from the Spanish Lymphoma Oncology Group
Authors: V. Calvo de Juan, M. Provencio, J. Gomez Codina, D. Rodriguez Abreu, A. Rueda, R. García Arroyo, Ldela Cruz Merino, M. Llanos, J. Guma I. Padro, J.J. Sánchez Hernández
Journal: Annals of Oncology (2016)
Phase II trial of panitumumab monotherapy for patients with KRAS exon2 wild type colorectal cancer after progression on cetuximab. HGCSG1101
Authors: S. Yuki, Y. Komatsu, T. Muranaka, K. Harada, J. Sugiyama, Y. Tsuji, T. Ando, A. Hosokawa, K. Hatanaka, H. Naruse, T. Takahata, A. Sato, Y. Kobayashi, T. Miyagishima, H. Okuda, M. Kudo, M. Nakamura, H. Hisai, N. Sakamoto, Y. Sakata
Journal: Annals of Oncology (2016)
AXL activation can promote resistance to MEK inhibition in a model of colorectal cancer (CRC)
Authors: G. Martini, V. Belli, P.P. Vitiello, T. Troiani, C. Cardone, S. Napolitano, V. Sforza, M.L. Ferrara, F. Morgillo, D. Ciardiello, E.F. Giunta, F. Ciardiello, E. Martinelli
Journal: Annals of Oncology (2016)
Analysis of Hypochromic Reticulocytes and Ferritin Index as a Rationale for An Effective Therapy of Cancer- and Chemotherapy-Associated Anemia
Authors: H. Tilman Steinmetz, Antonis Georg Tsamaloukas, Stephan Schmitz, Jörg Wiegand, Robert Rohrberg, Jochen Eggert, Heidi Eustermann, Hans-Werner Tessen, Lothar Thomas
Journal: Blood (2008)